Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Daiichi Sankyo Ltd.
Scientific Title
A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)